Agile Therapeutics (AGRX)

Agile Therapeutics (AGRX) Stock Price & Analysis


AGRX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.65 - $16.04
Previous Close$1.73
Average Volume (3M)49.21K
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$2.79M
Total Debt (Recent Filing)$2.19M
Price to Earnings (P/E)>-0.1
Nov 01, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-39.40
Shares Outstanding1,926,510
10 Day Avg. Volume41,452
30 Day Avg. Volume49,206
Standard Deviation0.32
Financial Highlights & Ratios
Price to Book (P/B)-0.29
Price to Sales (P/S)1.04
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Price Target Upside382.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Agile Therapeutics’s price range in the past 12 months?
Agile Therapeutics lowest stock price was $1.65 and its highest was $16.04 in the past 12 months.
    What is Agile Therapeutics’s market cap?
    Currently, no data Available
    When is Agile Therapeutics’s upcoming earnings report date?
    Agile Therapeutics’s upcoming earnings report date is Nov 01, 2023 which is in 40 days.
      How were Agile Therapeutics’s earnings last quarter?
      Agile Therapeutics released its earnings results on Aug 09, 2023. The company reported -$3.1 earnings per share for the quarter, beating the consensus estimate of -$4.945 by $1.845.
        Is Agile Therapeutics overvalued?
        According to Wall Street analysts Agile Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Agile Therapeutics pay dividends?
          Agile Therapeutics does not currently pay dividends.
          What is Agile Therapeutics’s EPS estimate?
          Agile Therapeutics’s EPS estimate is -$1.58.
            How many shares outstanding does Agile Therapeutics have?
            Agile Therapeutics has 1,926,510 shares outstanding.
              What happened to Agile Therapeutics’s price movement after its last earnings report?
              Agile Therapeutics reported an EPS of -$3.1 in its last earnings report, beating expectations of -$4.945. Following the earnings report the stock price went down -11.197%.
                Which hedge fund is a major shareholder of Agile Therapeutics?
                Among the largest hedge funds holding Agile Therapeutics’s share is Perceptive Advisors LLC. It holds Agile Therapeutics’s shares valued at 620K.


                  Agile Therapeutics Stock Smart Score

                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Agile Therapeutics

                  Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.


                  Top 5 ETFs holding AGRX

                  Market Value
                  Smart Score
                  iShares Core S&P Total U.S. Stock Market ETF
                  Up to five ETFs with an Outperform Smart Score that hold AGRX. The ETFs are listed according to market value of AGRX within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Aytu BioScience
                  Palatin Technologies
                  Acasti Pharma

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis